ATE355278T1 - Isochinolinon derivate als parp inhibitoren - Google Patents
Isochinolinon derivate als parp inhibitorenInfo
- Publication number
- ATE355278T1 ATE355278T1 AT02724438T AT02724438T ATE355278T1 AT E355278 T1 ATE355278 T1 AT E355278T1 AT 02724438 T AT02724438 T AT 02724438T AT 02724438 T AT02724438 T AT 02724438T AT E355278 T1 ATE355278 T1 AT E355278T1
- Authority
- AT
- Austria
- Prior art keywords
- parp inhibitors
- isoquinolinone derivatives
- isoquinolinone
- derivatives
- parp
- Prior art date
Links
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28963101P | 2001-05-08 | 2001-05-08 | |
| US34527402P | 2002-01-03 | 2002-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355278T1 true ATE355278T1 (de) | 2006-03-15 |
Family
ID=26965750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02724438T ATE355278T1 (de) | 2001-05-08 | 2002-04-30 | Isochinolinon derivate als parp inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6664269B2 (de) |
| EP (1) | EP1397350B1 (de) |
| JP (1) | JP2004528376A (de) |
| AT (1) | ATE355278T1 (de) |
| CA (1) | CA2444531A1 (de) |
| DE (1) | DE60218458T2 (de) |
| ES (1) | ES2282410T3 (de) |
| WO (1) | WO2002090334A1 (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| ES2357057T3 (es) | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
| DK1557414T3 (da) | 2002-10-01 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | IsoquinoIin-forbindelser og medicinsk anvendelse deraf |
| WO2004048339A1 (ja) * | 2002-11-22 | 2004-06-10 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EP1633724B1 (de) * | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinonderivative |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| TWI338000B (en) * | 2003-12-01 | 2011-03-01 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| WO2006021801A1 (en) * | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| EP1831225A2 (de) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Entzündungshemmende pyrazolopyrimidine |
| SI1928454T1 (sl) | 2005-05-10 | 2015-01-30 | Intermune, Inc. | Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema |
| AU2006257815A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | PARP modulators and treatment of cancer |
| SG164368A1 (en) | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| DK2004654T3 (da) | 2006-04-04 | 2013-07-22 | Univ California | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister |
| WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030891A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| US8367699B2 (en) * | 2006-09-15 | 2013-02-05 | Nexuspharma, Inc. | Tetrahydro-isoquinolines |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| BRPI0806371A2 (pt) | 2007-01-22 | 2011-09-13 | Gtx Inc | agentes ligação de receptor nuclear |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| GB2443760B (en) * | 2007-05-18 | 2008-07-30 | Cvon Innovations Ltd | Characterisation system and method |
| GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| WO2009046448A1 (en) * | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US8268827B2 (en) | 2007-11-15 | 2012-09-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. | Pyridazinone derivatives as PARP inhibitors |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (de) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinasehemmer und verwendungsverfahren |
| WO2009149188A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| WO2010006072A2 (en) * | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| NZ592719A (en) | 2008-10-07 | 2012-09-28 | Astrazeneca Uk Ltd | PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
| DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| GB0820856D0 (en) * | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| CA2798697A1 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3581574A1 (de) | 2011-01-10 | 2019-12-18 | Infinity Pharmaceuticals, Inc. | Zusammensetzung zur oralen verabreichung zur verwendung bei der behandlung von krebs, einer entzündungskrankheit oder einer autoimmunerkrankung |
| WO2012148540A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kanase inhibitors and uses threof |
| WO2013004652A1 (de) | 2011-07-04 | 2013-01-10 | Bayer Intellectual Property Gmbh | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| JP6027611B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| WO2013077921A2 (en) | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| US9422243B2 (en) * | 2011-11-25 | 2016-08-23 | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN102875466A (zh) * | 2012-04-23 | 2013-01-16 | 中国药科大学 | 异喹啉酮衍生物,其制备方法及其医药用途 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN104995192A (zh) | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| NZ708563A (en) | 2012-11-01 | 2019-02-22 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3964507A1 (de) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und verwendungen davon |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| MX2016012808A (es) | 2014-04-02 | 2017-01-05 | Intermune Inc | Piridinonas anti-fibroticas. |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2017002120A1 (en) * | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| BR112018002465A2 (pt) * | 2015-08-17 | 2018-09-18 | Lupin Ltd | derivados de heteroarila como inibidores de parp |
| EP3350183B1 (de) | 2015-09-14 | 2025-04-02 | Twelve Therapeutics, Inc. | Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verwendungsverfahren dafür |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| JP2020500214A (ja) | 2016-11-02 | 2020-01-09 | イミュノジェン・インコーポレーテッド | 抗体薬物複合体とｐａｒｐ阻害剤との併用治療 |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| DK4143182T3 (da) | 2020-04-28 | 2025-03-03 | Rhizen Pharmaceuticals Ag | Nye forbindelser, der er anvendelige som poly(adp-ribose)-polymerase (parp)-hæmmere |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| MX2023011793A (es) | 2021-04-08 | 2023-10-12 | Rhizen Pharmaceuticals Ag | Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE287032C (de) | ||||
| US2612503A (en) * | 1949-04-19 | 1952-09-30 | Smith Kline French Lab | Basic ether-substituted isoquinolines |
| GB721286A (en) | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
| DE2143745A1 (de) | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung |
| JPS54156526A (en) | 1978-05-31 | 1979-12-10 | Asahi Chemical Ind | Dry picture forming material |
| US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
| JPS58164577A (ja) | 1982-03-24 | 1983-09-29 | Taiho Yakuhin Kogyo Kk | ４―ベンジル―１―（２ｈ）イソキノロン誘導体 |
| US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| DE3640641A1 (de) | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US4897391A (en) | 1988-06-17 | 1990-01-30 | Schering Corporation | Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds |
| EP0355750B1 (de) | 1988-08-19 | 1995-01-25 | Warner-Lambert Company | Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren |
| JP2519179Y2 (ja) | 1989-03-29 | 1996-12-04 | 矢崎総業株式会社 | 電気コネクタにおける端子金具の二重係止構造 |
| GB9011833D0 (en) * | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
| EP0502575A1 (de) * | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituierte 1-(2H)-Isoquinolinone |
| IL104406A0 (en) * | 1992-01-17 | 1993-05-13 | Syntex Inc | Substituted 1-isoquinolone derivatives,their preparation and pharmaceutical compositions containing them |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| US6262068B1 (en) | 1997-02-21 | 2001-07-17 | Bristol-Myers Squibb Company | Lactam derivatives as antiarrhythmic agents |
| BR9809115A (pt) | 1997-05-13 | 2002-01-02 | Octamer Inc | Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt |
| WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| ATE261963T1 (de) | 1999-01-11 | 2004-04-15 | Agouron Pharma | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
-
2002
- 2002-04-30 DE DE60218458T patent/DE60218458T2/de not_active Expired - Fee Related
- 2002-04-30 US US10/135,247 patent/US6664269B2/en not_active Expired - Fee Related
- 2002-04-30 WO PCT/GB2002/001967 patent/WO2002090334A1/en active IP Right Grant
- 2002-04-30 CA CA002444531A patent/CA2444531A1/en not_active Abandoned
- 2002-04-30 EP EP02724438A patent/EP1397350B1/de not_active Expired - Lifetime
- 2002-04-30 AT AT02724438T patent/ATE355278T1/de not_active IP Right Cessation
- 2002-04-30 JP JP2002587414A patent/JP2004528376A/ja not_active Ceased
- 2002-04-30 ES ES02724438T patent/ES2282410T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2282410T3 (es) | 2007-10-16 |
| CA2444531A1 (en) | 2002-11-14 |
| JP2004528376A (ja) | 2004-09-16 |
| WO2002090334A1 (en) | 2002-11-14 |
| EP1397350B1 (de) | 2007-02-28 |
| US20030008896A1 (en) | 2003-01-09 |
| DE60218458D1 (de) | 2007-04-12 |
| DE60218458T2 (de) | 2007-11-15 |
| EP1397350A1 (de) | 2004-03-17 |
| US6664269B2 (en) | 2003-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| DE60112974D1 (en) | Carbolinderivate | |
| EE200200673A (et) | Kinasoliini derivaadid kasvajate raviks | |
| EA200200306A1 (ru) | Трициклические ингибиторы поли(адф-рибозо)полимераз | |
| IL152916A0 (en) | Heteroaryl-phenyl heterobicyclic factor xa inhibitors | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| SE9900100D0 (sv) | New compounds | |
| BR9806752A (pt) | Ftalazinonas. | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| DE60216233D1 (en) | Carbolinderivate | |
| DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
| SE9802208D0 (sv) | Novel compounds | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| EA200200742A1 (ru) | 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии | |
| DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
| IT1317751B1 (it) | Poliolefine di metalloceni stabilizzate. | |
| EE05241B1 (et) | Distamtsiini a-halogenoakrlolderivaadi kasutamine | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |